Ingersoll Rand Inc. has announced the acquisition of Dave Barry Plastics, further enhancing its life sciences portfolio. This strategic move aligns with Ingersoll Rand's commitment to expanding its offerings with high-performance solutions. Dave Barry Plastics, based in Ireland, specializes in designing and manufacturing custom plastic products for the biopharmaceutical, pharmaceutical, and medical device industries. The acquisition is expected to bolster Ingersoll Rand's capabilities within the life sciences sector, particularly in providing solutions for clean rooms. The transaction was made at an attractive purchase multiple of approximately 9x 2024 Adjusted EBITDA, emphasizing Ingersoll Rand's strategy of growth through direct investments and strong relationships with family-owned businesses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。